Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTX NASDAQ:EOLS NASDAQ:OCGN NASDAQ:OVID On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$1.75-3.8%$2.60$1.75▼$4.94$104.29M3.222.17 million shs2.31 million shsEOLSEvolus$6.73+3.4%$5.71$3.86▼$10.27$428.71M1.34696,948 shs635,584 shsOCGNOcugen$1.21-0.8%$1.54$0.90▼$2.73$413M2.194.96 million shs3.73 million shsOVIDOvid Therapeutics$2.30+4.1%$2.60$0.27▼$3.11$412.48M0.161.42 million shs2.06 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-1.62%-13.13%-35.69%-14.15%-23.21%EOLSEvolus-3.13%-1.36%+0.15%+29.94%-36.43%OCGNOcugen+2.52%-10.95%-17.01%-50.81%+5.17%OVIDOvid Therapeutics-3.07%-10.89%-23.00%+12.18%+593.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$1.75-3.8%$2.60$1.75▼$4.94$104.29M3.222.17 million shs2.31 million shsEOLSEvolus$6.73+3.4%$5.71$3.86▼$10.27$428.71M1.34696,948 shs635,584 shsOCGNOcugen$1.21-0.8%$1.54$0.90▼$2.73$413M2.194.96 million shs3.73 million shsOVIDOvid Therapeutics$2.30+4.1%$2.60$0.27▼$3.11$412.48M0.161.42 million shs2.06 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-1.62%-13.13%-35.69%-14.15%-23.21%EOLSEvolus-3.13%-1.36%+0.15%+29.94%-36.43%OCGNOcugen+2.52%-10.95%-17.01%-50.81%+5.17%OVIDOvid Therapeutics-3.07%-10.89%-23.00%+12.18%+593.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 2.73Moderate Buy$10.00471.43% UpsideEOLSEvolus 2.50Moderate Buy$16.00137.74% UpsideOCGNOcugen 2.60Moderate Buy$9.50685.12% UpsideOVIDOvid Therapeutics 2.89Moderate Buy$5.13122.83% UpsideCurrent Analyst Ratings BreakdownLatest BDTX, OVID, EOLS, and OCGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026OCGNOcugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/29/2026EOLSEvolus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/27/2026OCGNOcugen Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $11.005/22/2026BDTXBlack Diamond Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/22/2026BDTXBlack Diamond Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/18/2026BDTXBlack Diamond Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/18/2026OCGNOcugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026OVIDOvid Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.005/13/2026EOLSEvolus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond Therapeutics$70M1.43$0.51 per share3.45$1.97 per share0.89EOLSEvolus$297.18M1.49N/AN/A($0.36) per share-18.69OCGNOcugen$4.41M92.88N/AN/A($0.04) per share-30.25OVIDOvid Therapeutics$7.25M59.21N/AN/A$1.00 per share2.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics$22.37M-$0.77N/AN/AN/AN/A-30.18%-23.91%8/6/2026 (Estimated)EOLSEvolus-$51.64M-$0.67N/A112.17N/A-14.39%N/A-19.03%8/4/2026 (Estimated)OCGNOcugen-$67.85M-$0.24N/AN/AN/A-1,192.18%-127,987.80%-135.48%7/30/2026 (Estimated)OVIDOvid Therapeutics-$17.41M-$0.29N/AN/AN/A-240.11%-22.51%-18.67%8/12/2026 (Estimated)Latest BDTX, OVID, EOLS, and OCGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026OVIDOvid Therapeutics-$0.12-$0.12N/A-$0.12$0.06 millionN/A5/7/2026Q1 2026BDTXBlack Diamond Therapeutics-$0.18-$0.16+$0.02-$0.16$25.00 millionN/A5/5/2026Q1 2026OCGNOcugen-$0.05-$0.06-$0.01-$0.06$0.42 million$1.53 million5/4/2026Q1 2026EOLSEvolus-$0.14-$0.16-$0.02-$0.16$72.52 million$73.14 million3/18/2026Q4 2025OVIDOvid Therapeutics-$0.10$0.06+$0.16$0.06$0.06 million$0.72 million3/16/2026Q4 2025BDTXBlack Diamond Therapeutics-$0.18-$0.14+$0.04-$0.27$9.38 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A8.468.46EOLSEvolusN/A2.041.68OCGNOcugen4.171.861.86OVIDOvid Therapeutics0.0610.1710.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%EOLSEvolus90.69%OCGNOcugen10.27%OVIDOvid Therapeutics72.24%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics9.29%EOLSEvolus5.00%OCGNOcugen3.95%OVIDOvid Therapeutics7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9057.30 million51.98 millionOptionableEOLSEvolus17065.86 million62.56 millionOptionableOCGNOcugen80338.52 million325.15 millionOptionableOVIDOvid Therapeutics60186.64 million173.58 millionOptionableBDTX, OVID, EOLS, and OCGN HeadlinesRecent News About These CompaniesAnalysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Ovid Therapeutics (OVID) and Establishment Labs Holdings (ESTA)June 9 at 3:34 PM | theglobeandmail.comOvid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJune 9 at 3:11 AM | americanbankingnews.comOvid Therapeutics to Participate in Upcoming Investor ConferencesJune 4, 2026 | globenewswire.comOvid Therapeutics Expands Board, Appoints New Scientific DirectorJune 3, 2026 | tipranks.comOvid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of DirectorsJune 3, 2026 | globenewswire.comOvid Therapeutics: Advancing Seizure Pipeline and Neuropsychiatric Programs Support Buy Rating and Unchanged $4 Price TargetMay 26, 2026 | tipranks.comFormer Ovid CEO Dr. Jeremy Levin’s rallying cry for biotechMay 15, 2026 | finance.yahoo.comWe're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash WiselyMay 14, 2026 | finance.yahoo.comOvid Therapeutics Reports Business Updates and First Quarter 2026 Financial ResultsMay 12, 2026 | globenewswire.comHere is Why Ovid Therapeutics (OVID) is One of the Best Fast Growing Penny StocksMay 9, 2026 | insidermonkey.com5 Best Fast Growing Penny Stocks to Buy Right NowMay 8, 2026 | insidermonkey.comOvid Therapeutics Inc.April 20, 2026 | edition.cnn.comAnalysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Ovid Therapeutics (OVID) and Legend Biotech (LEGN)April 17, 2026 | theglobeandmail.comOvid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders - SlideshowApril 15, 2026 | seekingalpha.comOvid Therapeutics: Differentiated KCC2 ‘Master Switch’ Platform and Strong Cash Runway Underpin Buy RatingApril 15, 2026 | tipranks.comOvid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders TranscriptApril 14, 2026 | seekingalpha.comOvid Therapeutics: Undervalued KCC2 Platform and Upcoming OV4071 Catalyst Support Buy RatingApril 9, 2026 | tipranks.comOvid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14April 8, 2026 | globenewswire.comOvid Therapeutics (OVID) price target increased by 14.29% to 4.87March 27, 2026 | msn.comAnalysts Are Bullish on Top Healthcare Stocks: Sera Prognostics (SERA), Ovid Therapeutics (OVID)March 20, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesQuantum Stocks Just Got a Lifeline—Who Benefits Most?By Nathan Reiff | May 26, 20263 AI Data Center Stocks Worth Watching for Capital RotationBy Ryan Hasson | May 15, 2026HIVE Weaponizes Power for an AI PivotBy Jeffrey Neal Johnson | May 19, 2026As Small-Cap Outperformance Continues, These 2 ETFs Provide ExposureBy Jessica Mitacek | May 21, 2026Why Home Depot’s Sell-Off Could Become a Huge OpportunityBy Thomas Hughes | May 19, 2026BDTX, OVID, EOLS, and OCGN Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$1.75 -0.07 (-3.85%) Closing price 04:00 PM EasternExtended Trading$1.80 +0.04 (+2.57%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Evolus NASDAQ:EOLS$6.73 +0.22 (+3.38%) Closing price 04:00 PM EasternExtended Trading$6.66 -0.08 (-1.11%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Ocugen NASDAQ:OCGN$1.21 -0.01 (-0.82%) Closing price 04:00 PM EasternExtended Trading$1.20 0.00 (-0.41%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.Ovid Therapeutics NASDAQ:OVID$2.30 +0.09 (+4.07%) Closing price 04:00 PM EasternExtended Trading$2.28 -0.02 (-0.70%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
